# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Arthur He reiterates LAVA Therapeutics (NASDAQ:LVTX) with a Buy and maintains $6 price target.
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $...
https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20240067726
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earning...
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow ...